

Fact Sheet PET NET: Ontario ⁶⁸Ga-DOTATATE PET Registry

As of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria have access to ⁶⁸Ga-DOTATATE PET scanning in Ontario as part of "PET NET", a Health Canada approved registry.

What PET centres will be able to provide ⁶⁸Ga-DOTATATE PET scans?

PET NET will initially provide scans at the University Health Network (UHN), Princess Margaret Cancer Centre in Toronto, leveraging the existing infrastructure in place as part of the Ontario NETs Lu-177 Trial. In the future expansion to additional sites will be considered as provincial demand grows, providing greater access and minimizing travel burden for patients.

Note that patients who prefer to have their scan performed in another province (e.g., Sherbrooke, Quebec) may continue to do so upon approval. In this case, please refer to PET Scans Ontario as you have been for case by case approval; PET NET criteria will be applied to those referrals to support a consistent approach.

If you have a patient already referred to PET Access or awaiting scanning in Sherbrooke, you may choose to have the referral redirected to UHN. Please contact the PET Scans Ontario Information Line (1-877-473-8411) to initiate that process.

What indications are included?

Indications (clinical scenarios) covered by PET NET, informed by the <u>Recommendation Report</u> summarizing the clinical evidence regarding Ga68-DOTATATE PET (reference below), include:

- **DIAGNOSIS** PET for identification of primary tumour when there is clinical suspicion of NET, and primary tumour site is unknown or uncertain.
- **STAGING** PET for the staging of patients upon initial presentation of NET.
- RE-STAGING PET for the re-staging of patients with NET a) when surgery or PRRT is being
 considered; OR b) where conventional imaging is negative or equivocal at time of clinical and/or
 biochemical progression
- *OTHER PET as a problem-solving tool in patients with NET when confirmation of site of disease and/or disease extent may impact clinical management. (will be assessed on a case by case basis, facilitated by the PET centre and CCO's PET Access Program)

To refer a patient for a ⁶⁸Ga-DOTATATE PET scan:

- Physicians complete the ⁶⁸Ga-DOTATATE PET Requisition Form, and fax the Requisition Form and supporting documentation (as identified on Form) directly to UHN, Princess Margaret Cancer Centre (PET centre) at fax #: 416-946-2144.
 - The nature of the provision of ⁶⁸Ga-DOTATATE means that scanning must be spaced in time; patients will be booked according to clinical priority. If a patient's status changes between the time of referral and scan, we recommend the referring clinician connect directly with the PET centre to discuss.
- Access to the ⁶⁸Ga-DOTATATE PET is facilitated through a Health Canada study, and thus
 patients must have provided consent to the Health Canada study to receive the PET scan.



PET Scans Ontario



- Patients meeting eligibility will be contacted by the Study Coordinator for booking and
 initial verbal consent to proceed. The PET scan will be booked, and consent forms will be
 provided to patients in advance to provide opportunity for review and to ask questions; patients
 will provide their final written consent when they arrive for their PET scan appointment.
- After the scan:
 - Referring Physicians will receive a report on the ⁶⁸Ga-DOTATATE PET scan following usual clinical practices.
 - Referring Physicians complete a short Summary of Intended Treatment Plan (Post Scan)
 - o The PET centre completes a Summary of PET Findings

Together with the referral form, this package completes all information to assess impact of the PET on patient care and comply with all regulatory conditions of the Registry.

Questions regarding PET NET requisitions or consent process? Contact <u>PETNET@uhnresearch.ca</u>

General PET Scans Ontario questions? Contact PET Scans Ontario at 1-877-4PET-411

Additional Resources:

Ontario's PET Scan Program:

www.petscansontario.ca

PET Scans Ontario Information Line (1-877-473-8411).

CCO Resources for NETs:

Recommendation Report – Gallium-68 PET Imaging in Neuroendocrine Tumours: https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/57516

Radionuclide Therapy for Neuroendocrine Tumours Program:

https://www.cancercareontario.ca/en/cancer-care-ontario/programs/clinical-services/specialized-services-oversight/radionuclide-therapy-neuroendocrine-tumours

